Skip to Content
Merck

Inhibition of cytochrome P450 by ethambutol in human liver microsomes.

Toxicology letters (2014-06-10)
Sang Yoon Lee, Himchan Jang, Ji-Yoon Lee, Kwang-il Kwon, Soo Jin Oh, Sang Kyum Kim
ABSTRACT

Although cytochrome P450 inhibition is the major drug-drug interaction (DDI) mechanism in clinical pharmacotherapy, DDI of a number of well-established drugs have not been investigated. Rifampicin, isoniazid, pyrazinamide and ethambutol combination therapy inhibits clearance of theophylline in patients with tuberculosis. We determined the inhibitory effects of ethambutol on the activities of nine CYP isoforms including CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4 in pooled human liver microsomes (HLM). As measured by liquid chromatography-electrospray ionization tandem mass spectrometry, ethambutol exhibited strong inhibitory potential against CYP1A2 and CYP2E1, moderate against CYP2C19 and CYP2D6 and weak against CYP2A6, CYP2C9 and CYP3A4, based on the IC50 values. The K(i) value of ethambutol for CYP1A2 was 1.4 μM and for CYP2E1 was 2.9 μM. Inhibition of CYP1A2 and CYP2E1 was not increased by preincubation with ethambutol and β-nicotinamideadenine dinucleotide phosphate (NADPH), suggesting that the ethambutol-induced CYP inhibition may not be metabolism-dependent. Kinetic analysis showed that the inhibition of CYP1A2 and CYP2E1 by ethambutol was best fit to a competitive inhibition model. Formation of 1-methylxanthene and 1,3-dimethyluric acid from theophylline in HLM was decreased to 47% and 36%, respectively, by 3.0 μM ethambutol, which is comparable to its IC50 value against CYP1A2. Considering its maximal plasma concentrations of ~10 μM and long half-life of ~22 h, our findings raise the possibility that ethambutol causes significant DDIs in clinical situations with drugs with narrow therapeutic index, such as theophylline, in clinical situations.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Phenacetin, ≥98.0% (HPLC)
Supelco
Testosterone, VETRANAL®, analytical standard
Sigma-Aldrich
Carbamazepine, meets USP testing specifications
Sigma-Aldrich
Potassium phosphate tribasic, reagent grade, ≥98%
Sigma-Aldrich
Theophylline, anhydrous, ≥99%, powder
Supelco
Phenacetin melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material
Testosterone, European Pharmacopoeia (EP) Reference Standard
USP
Phenacetin Melting Point Standard, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Ethambutol dihydrochloride, antimycobacterial
Sigma-Aldrich
Carbamazepine, powder
Sigma-Aldrich
Coumarin, ≥99% (HPLC)
Sigma-Aldrich
Testosterone, purum, ≥99.0% (HPLC)
Coumarin, primary reference standard
Supelco
Theophylline, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Carbamazepine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Phenacetin, Pharmaceutical Secondary Standard; Certified Reference Material
Paracetamol, European Pharmacopoeia (EP) Reference Standard
Theophylline, European Pharmacopoeia (EP) Reference Standard
USP
Theophylline, United States Pharmacopeia (USP) Reference Standard
Supelco
Testosterone solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
USP
Carbamazepine, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Testosterone, ≥98%
Supelco
Carbamazepine, analytical standard
Ethambutol hydrochloride, European Pharmacopoeia (EP) Reference Standard
Carbamazepine, European Pharmacopoeia (EP) Reference Standard
Coumarin, European Pharmacopoeia (EP) Reference Standard
Supelco
Coumarin, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
Acetaminophen, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ketoconazole
Sigma-Aldrich
4-Hydroxytolbutamide, ≥98% (HPLC)